Next Phase Newsletter

A firm founded in 2014 and based in Silicon Valley invests in several fields including digital health, healthcare IT, and medical devices. The firm is currently raising its second fund, and typically invests an average of $300,000 per company, though this is dependent on the technology as the investment size may increase, particularly for hardware-based technology. The firm typically co-invests at present but is anticipating leading investments with the new fund. The firm typically makes 12-20 new investments per year, and focuses on companies based in North America (USA & Canada), though is open to looking at companies based on a global-level. Furthermore, the firm has a considerable value-add in supporting companies that may be interested in moving their markets to Asia by passing potential deals to the firm’s Shanghai office as its source of deal flow, and making the right introductions to Asian investors and/or distribution partners.

The firm is open to all subsectors of digital health, healthcare IT, diagnostics, mobile app healthcare technologies, and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage.

The firm does not have a particular management team requirement. The firm will help the company fill the team if necessary. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm with offices worldwide manages a $30 million seed-stage fund that seeks to invest in companies across a variety of industries, but it is most interested in A.I. technology and data-oriented companies. The investment is general in term of equity, but convertible loans will be considered as well. The typical investment size ranges from $250K to $500K and seeks 25 new investments per year. The fund generally invests in seed stage, but occasionally will invest in Series A and Series B rounds with co-investors. The firm will consider new opportunities around the globe.

In healthcare, the firm is currently looking for new investments in the medical technology and healthcare IT sectors. The firm will not consider investments in biotech therapeutics or drug development space. For medical devices, the firm considers Class 1&2 devices, depending on the opportunity, but it is most interested in low-risk devices that do not need FDA approval. In healthcare IT, the firm looks to invest in companies developing m-Health and e-Health. In terms of stage of development, the current fund focuses on seed-stage investments. Historically, the firm was active in companies targeting digital health and clinical data platform.

The firm looks to invest in private companies across the globe. The firm prefers to invest in companies with a strong and full management team with significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global alternative asset manager based in Shenzhen, China focuses on investments in the healthcare sector, currently focusing on acquisition or investment first and then acquisition. The firm is making new investments in venture stage companies from its 2015 vintage fund of US$50 million. Depending on the stage of the company, the firm can invest from several hundred thousand to tens of millions in companies with valuation under 1 billion RMB. The firm considers companies based in the US, Europe, Israel, and Asia with a focus on China-based businesses. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking to invest in medical devices that are novel and disruptive. The firm considers a broad range of medical devices with a focus on robotics, cardiovascular, cancer, diabetes, orthopedics, and ophthalmology. The firm typically invests in clinical stage projects but would consider devices at all stages.

Currently, the firm is only looking for privately held companies and typically requires board representation post-investment. The firm prefers to exit within 5 years, but can be flexible on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A California-based firm backed by strategic LPs closed its first fund in early 2016. The firm invests in early stage healthcare technologies that are strategically relevant to its LPs, which are major foreign corporations. The firm has a fund size of $75 million and is a multi-stage investor, interested in companies from the seed stage through to late-stage venture rounds. Investments therefore vary by stage, but the firm’s Series A investments may typically be of about $1-3 million. The firm generally prefers to act as a co-investor. The firm is focused on US-based opportunities.

The firm is interested in new technologies in digital health, medical devices, diagnostics, and therapeutics. The firm’s primary focus is on the intersection between data and biotech, diagnostics and medical devices, with microfluidics, connected devices, digitization, and automation being areas of high interest. For therapeutics, the firm generally does not invest in single-asset companies; therapeutic platform technologies that have the potential to create multiple ‘shots on goal’ are preferred. The firm prefers to focus on patients for whom there is high unmet need and no currently adequate treatments; rare diseases are of high interest. The firm is a multi-stage investor, and is open to investing in assets as early as the preclinical or pre-prototype stage.

The firm seeks management teams that display knowledge of how to build a business out of a strong technology. The firm focuses on technologies that allow the firm’s LPs to provide a value-add in partnering, manufacturing or distribution; healthcare technologies involving sensors and materials science are high focus areas. The firm evaluates opportunities on a technical, clinical and leadership level; the firm then shares the results of their diligence with the company in order to help the company in their future efforts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in St. Louis, Missouri, prefers to make growth-stage, equity investments in a variety of sectors, including the life sciences, typically in the $2M-$10M range. The firm prefers to lead rounds, but will also syndicate deals. The firm’s first fund closed late in 2015, and is targeting between 3 and 5 investments per year, focusing on the Midwestern United States. However, this includes all states except for those in the North East and those on the West Coast.

Within the Life Science space, the firm is primarily interested in data-driven, connected medical devices and diagnostics as well as any technology that improves drug adherence (mobile apps, devices, etc.). The firm has deep domain experience in IT and is therefore very interested in healthcare IT, such as enterprise software solutions. In addition, life science tools are also an area of interest. The firm is open to all sectors within the life sciences, with the exception of therapeutics, and requires that the product is already FDA approved or is exempt from regulatory approval.

The firm prefers to work with experienced management teams and serial entrepreneurs, however the firm is open to working with first-time entrepreneurs. The firm prefers to lead rounds and requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel network founded in 2006 and based in Illinois looks to make seed and venture investments generally ranging from $200K to $2M. The group prefers to invest in companies with pre-money valuations of less than $5 million. While the firm prefers to invest in the Midwestern US they are also open to investing as a member of a syndicate in other regions of the United States.

In the life science space, the group is currently interested in companies working with medical technology, healthcare IT and healthcare services/analytics. In terms of healthcare IT, companies with a B2B or B2C (including wearables) focus are both of interest. The group does not invest in drug development/biopharma companies. The group is looking for companies with Class I and II devices that have a defined 510k regulatory pathway with a clear route to commercialization. The group is open to all indication types within this area, prefers company with the potential to reach commercialization in 6-12 months.

The group is looking for privately held companies with experienced management teams, and looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over US$4.5 billion. The firm is current investing from its newest US$100 million and RMB 1 billion funds that are set to close in 2016. Typical equity allocations range from US$2-6 million in an early stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, US, and EU.

The firm invests across various sectors in life sciences. In pharmaceuticals, the firm is looking for innovative assets in the pre-clinical phase and is open to both small molecules and biologics. The firm focuses on diseases with large market potential such as oncology and cardiovascular conditions. In MedTech, the firm is looking for concept stage or post-prototype products that have large market potential and high entry battier.

The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angel; however, this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of joint venture and strategic partnership in the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com